BR112023000515A2 - Composição farmacêutica e seu uso - Google Patents
Composição farmacêutica e seu usoInfo
- Publication number
- BR112023000515A2 BR112023000515A2 BR112023000515A BR112023000515A BR112023000515A2 BR 112023000515 A2 BR112023000515 A2 BR 112023000515A2 BR 112023000515 A BR112023000515 A BR 112023000515A BR 112023000515 A BR112023000515 A BR 112023000515A BR 112023000515 A2 BR112023000515 A2 BR 112023000515A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- conjugate
- relates
- present
- liver disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
COMPOSIÇÃO FARMACÊUTICA E SEU USO. A presente invenção refere-se ao uso terapêutico de um derivado de glucagon ou um conjugado do mesmo para doença hepática.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200087684 | 2020-07-15 | ||
PCT/KR2021/009124 WO2022015082A1 (ko) | 2020-07-15 | 2021-07-15 | 글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023000515A2 true BR112023000515A2 (pt) | 2023-03-21 |
Family
ID=79555736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023000515A BR112023000515A2 (pt) | 2020-07-15 | 2021-07-15 | Composição farmacêutica e seu uso |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230310631A1 (pt) |
EP (1) | EP4183407A1 (pt) |
JP (1) | JP2023534949A (pt) |
KR (1) | KR20220009354A (pt) |
CN (1) | CN116096397A (pt) |
AU (1) | AU2021308828A1 (pt) |
BR (1) | BR112023000515A2 (pt) |
CA (1) | CA3186097A1 (pt) |
IL (1) | IL299778A (pt) |
MX (1) | MX2023000698A (pt) |
WO (1) | WO2022015082A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230095666A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 간 표적 물질 및 이의 용도 |
KR20240086758A (ko) * | 2022-11-30 | 2024-06-19 | 주식회사 마이크로바이오틱스 | 대변 미생물총 이식용 이중캡슐 및 이의 제조방법 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
AU2006280587B2 (en) | 2005-08-16 | 2011-02-24 | Hanmi Science Co., Ltd. | A method for the mass production of immunoglobulin Fc region deleted initial methionine residues |
EP2864351B1 (en) * | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
PE20171154A1 (es) | 2014-12-30 | 2017-08-16 | Hanmi Pharm Ind Co Ltd | Derivados de glucagon con estabilidad mejorada |
TWI700291B (zh) * | 2015-06-22 | 2020-08-01 | 美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
MX2017016845A (es) | 2015-06-30 | 2018-08-01 | Hanmi Pharm Ind Co Ltd | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo. |
UA126662C2 (uk) * | 2016-06-29 | 2023-01-11 | Ханмі Фарм. Ко., Лтд. | Похідна глюкагону, її кон'югат, композиція, яка її містить, та її терапевтичне застосування |
-
2021
- 2021-07-15 KR KR1020210093028A patent/KR20220009354A/ko unknown
- 2021-07-15 CN CN202180054756.2A patent/CN116096397A/zh active Pending
- 2021-07-15 CA CA3186097A patent/CA3186097A1/en active Pending
- 2021-07-15 WO PCT/KR2021/009124 patent/WO2022015082A1/ko unknown
- 2021-07-15 IL IL299778A patent/IL299778A/en unknown
- 2021-07-15 JP JP2023502759A patent/JP2023534949A/ja active Pending
- 2021-07-15 BR BR112023000515A patent/BR112023000515A2/pt unknown
- 2021-07-15 AU AU2021308828A patent/AU2021308828A1/en active Pending
- 2021-07-15 MX MX2023000698A patent/MX2023000698A/es unknown
- 2021-07-15 US US18/016,165 patent/US20230310631A1/en active Pending
- 2021-07-15 EP EP21842945.4A patent/EP4183407A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230310631A1 (en) | 2023-10-05 |
CA3186097A1 (en) | 2022-01-20 |
IL299778A (en) | 2023-03-01 |
KR20220009354A (ko) | 2022-01-24 |
MX2023000698A (es) | 2023-04-18 |
JP2023534949A (ja) | 2023-08-15 |
EP4183407A1 (en) | 2023-05-24 |
WO2022015082A1 (ko) | 2022-01-20 |
CN116096397A (zh) | 2023-05-09 |
AU2021308828A1 (en) | 2023-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021012222A8 (pt) | Molécula de ligação direcionada à célula melhorada | |
BR112023000515A2 (pt) | Composição farmacêutica e seu uso | |
UY38425A (es) | Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste | |
BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
BR112019011139A2 (pt) | conjugados que compreendem um agonista dual de glp/glucagon, um ligante e ácido hilaurônico | |
BR112022003589A2 (pt) | Conjugado de anticorpo-fármaco compreendendo anticorpo contra ror1 humano e uso para o mesmo | |
BRPI0821115A8 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
BR112021017303A2 (pt) | Conjugado de anticorpo ou um sal ou solvato farmaceuticamente aceitável deste, anticorpo que se liga com especificidade ao dlk1 ou um fragmento de ligação ao antígeno deste, composição farmacêutica para prevenção ou tratamento de doença proliferativa, câncer ou angiogênica, métodos para prevenção e para tratamento de doença proliferativa, câncer ou angiogênica, e, uso do conjugado | |
BR112022003514A2 (pt) | Degradadores bifuncionais de brd9 e seus métodos de uso | |
DOP2007000053A (es) | Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo | |
BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
BRPI0821855B8 (pt) | composto, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
BRPI0706992C1 (pt) | composto de fórmula (i) e formulação farmacêutica | |
BR112019005318A2 (pt) | compostos de aza-indazol para uso em lesões no tendão e/ou ligamento | |
BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
BR112022023983A2 (pt) | Compostos terapêuticos | |
BR112022010798A2 (pt) | Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo | |
BR112023001143A2 (pt) | Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo | |
BR112019007863A2 (pt) | derivados de naftiridinona inovadores e seu uso no tratamento de arritmia | |
BR112022019518A2 (pt) | Composição farmacêutica para prevenir ou tratar mucosite induzida por radioterapia, quimioterapia, ou uma combinação das mesmas, que compreende derivados de glp-2 ou um conjugado de atuação duradoura do mesmo | |
BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
BR112022014278A2 (pt) | Conjugados de composto proteico-antiviral | |
BR112022008039A2 (pt) | Compostos de 4-amino-imidazoquinolina e usos relacionados | |
BR112019005578A2 (pt) | compostos de indazol para uso em lesões no tendão e/ou ligamento | |
BR112023026735A2 (pt) | Conjugado, composto de conector-fármaco, uso de um composto de conector-fármaco, e, composição farmacêutica |